Literature DB >> 25183853

Melanoma: clinical features and genomic insights.

Elena B Hawryluk1, Hensin Tsao2.   

Abstract

Recent efforts in genomic research have enabled the characterization of molecular mechanisms underlying many types of cancers, ushering novel approaches for diagnosis and therapeutics. Melanoma is a molecularly heterogeneous disease, as many genetic alterations have been identified and the clinical features can vary. Although discoveries of frequent mutations including BRAF have already made clinically significant impact on patient care, there is a growing body of literature suggesting a role for additional mutations, driver and passenger types, in disease pathophysiology. Although some mutations have been strongly associated with clinical phenotypes of melanomas (such as physical distribution or morphologic subtype), the function or implications of many of the recently identified mutations remains less clear. The phenotypic and clinical impact of genomic mutations in melanoma remains a promising opportunity for progress in the care of melanoma patients.
Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183853      PMCID: PMC4143108          DOI: 10.1101/cshperspect.a015388

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  113 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.

Authors:  A Birck; V Ahrenkiel; J Zeuthen; K Hou-Jensen; P Guldberg
Journal:  J Invest Dermatol       Date:  2000-02       Impact factor: 8.551

3.  Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.

Authors:  Patrick Terheyden; Roland Houben; Parisa Pajouh; Christoph Thorns; Detlef Zillikens; Jürgen C Becker
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

4.  Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism.

Authors:  Irene Sánchez-Hernández; Pablo Baquero; Laura Calleros; Antonio Chiloeches
Journal:  Cancer Lett       Date:  2011-10-08       Impact factor: 8.679

Review 5.  Sorafenib in melanoma.

Authors:  Joanna Mangana; Mitchell P Levesque; Maria B Karpova; Reinhard Dummer
Journal:  Expert Opin Investig Drugs       Date:  2012-03-07       Impact factor: 6.206

6.  'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplification.

Authors:  Elena B Hawryluk; Johanna L Baran; Pedram Gerami; Alireza Sepehr
Journal:  J Cutan Pathol       Date:  2013-01       Impact factor: 1.587

Review 7.  Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.

Authors:  Thomas Hocker; Hensin Tsao
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

8.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

9.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

10.  An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.

Authors:  Devarati Mitra; Xi Luo; Ann Morgan; Jin Wang; Mai P Hoang; Jennifer Lo; Candace R Guerrero; Jochen K Lennerz; Martin C Mihm; Jennifer A Wargo; Kathleen C Robinson; Suprabha P Devi; Jillian C Vanover; John A D'Orazio; Martin McMahon; Marcus W Bosenberg; Kevin M Haigis; Daniel A Haber; Yinsheng Wang; David E Fisher
Journal:  Nature       Date:  2012-10-31       Impact factor: 49.962

View more
  14 in total

1.  The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo.

Authors:  N Dana; S Haghjooy Javanmard; G Vaseghi
Journal:  Clin Transl Oncol       Date:  2019-06-07       Impact factor: 3.405

2.  Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Piotr Waloszczyk; Marek Masiuk; Jaroslaw Wejman; Justyna Szumilo; Markku Miettinen
Journal:  Mod Pathol       Date:  2019-02-13       Impact factor: 7.842

3.  Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.

Authors:  Kevin M Poindexter; Susanne Matthew; Ida Aronchik; Gary L Firestone
Journal:  Cell Biol Toxicol       Date:  2016-04-07       Impact factor: 6.691

Review 4.  Melanocytes and their diseases.

Authors:  Yuji Yamaguchi; Vincent J Hearing
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

Review 5.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

6.  Prognostic significance of β2-adrenergic receptor expression in malignant melanoma.

Authors:  Akira Shimizu; Kyoichi Kaira; Keita Mori; Madoka Kato; Kimihiro Shimizu; Masahito Yasuda; Ayumi Takahashi; Tetsunari Oyama; Takayuki Asao; Osamu Ishikawa
Journal:  Tumour Biol       Date:  2015-11-23

7.  Clinical and Pathological Significance of ER Stress Marker (BiP/GRP78 and PERK) Expression in Malignant Melanoma.

Authors:  Akira Shimizu; Kyoichi Kaira; Masahito Yasuda; Takayuki Asao; Osamu Ishikawa
Journal:  Pathol Oncol Res       Date:  2016-08-08       Impact factor: 3.201

Review 8.  Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.

Authors:  Hassan Sadozai; Thomas Gruber; Robert Emil Hunger; Mirjam Schenk
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

9.  Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo.

Authors:  Ho-Chung Chen; Jairo Sierra; Lumeng Jenny Yu; Robert Cerchio; Brian A Wall; James Goydos; Suzie Chen
Journal:  Oncotarget       Date:  2017-12-23

10.  New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.

Authors:  Emmanuelle Bourneuf; Jordi Estellé; Amandine Blin; Françoise Créchet; Maria Del Pilar Schneider; Hélène Gilbert; Myriam Brossard; Amaury Vaysse; Mark Lathrop; Silvia Vincent-Naulleau; Florence Demenais
Journal:  Oncotarget       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.